SCHEMBL3023448

SCHEMBL3023448

Cc1ccccc1-c1csc(N2CCN(S(=O)(=O)c3ccc(C(C)(C)C)cc3)CC2)n1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 11/20 0.59
ALDH1A1 P00352 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
TDP1 Q9NUW8 1/20 0.52
USP2 O75604 1/20 0.48
MAPT P10636 1/20 0.48
RECQL P46063 1/20 0.48
HSD17B10 Q99714 1/20 0.48
LMNA P02545 2/20 0.48
MAPK1 P28482 1/20 0.48
GBA1 P04062 2/20 0.48
MAOA P21397 1/20 0.46
GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3650605 0.93 HSD11B1 (0.52) HSD11B1ALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL3007848 0.92 HSD11B1 (0.54) HSD11B1ALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL3008014 0.89 L3MBTL1 (0.57) HSD11B1ALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL3008797 0.89 HSD11B1 (0.57) HSD11B1ALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL3015553 0.88 AR (0.57) HSD11B1ALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL3021301 0.88 SMN1; SMN2 (0.55) ALDH1A1SMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL3006385 0.88 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL3017725 0.88 SMN1; SMN2 (0.55) ALDH1A1SMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL3011478 0.87 MAPT (0.55) HSD11B1ALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL3006930 0.86 MEN1 (0.66) HSD11B1ALDH1A1SMN1; SMN2L3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA HSD11B1 1034/4885ALDH1A1 3510/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.